Hideki Furukawa

USPTO Granted Patents = 15 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 6.9

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Chigasaki, JP (2021)
Fujisawa, JP (2017 - 2022)
Kanagawa, JP (2015 - 2023)

Company Filing History:

Takeda Pharmaceutical Company Limited

patents

2 out of 129

Tokyo Medical and Dental University

patents

4. 1 out of 712

The Rockefeller University

Takeda Pharmaceutical Company Limied

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12305169 - BBB-crossing lipid ligand of hetero nucleic acid (2025-05-20),

2. 11597928 - Nucleic acid complex (2023-03-07),

3. 11231298 - Sensor, sensor substrate, and sensor manufacturing method (2022-01-25),

4. 11192893 - Pyrazoloquinazolinone antitumor agents (2021-12-07),

5. 11186565 - Aromatic compound (2021-11-30),

6. 10968231 - Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders (2021-04-06),

7. 10968178 - IP6K inhibitors (2021-04-06),

8. 10670430 - Sensor (2020-06-02),

9. 10458817 - Sensor manufacturing method and sensor (2019-10-29),

10. 10379111 - Target substance capturing device (2019-08-13),

11. 10378932 - Sensor having generating and detecting units on a substrate with a curve or bent shape in a cylindrical housing and method of manufacturing sensor (2019-08-13),

12. 10337892 - Sensor and method of manufacturing sensor (2019-07-02),

13. 10139252 - Optical sensor (2018-11-27),

14. 9776962 - Aromatic compounds with GPR40 agonistic activity (2017-10-03),

15. 9073864 - Aromatic ring compound (2015-07-07),

Title: Innovations of Hideki Furukawa

Introduction

Hideki Furukawa is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of nucleic acid delivery systems, particularly in overcoming the challenges posed by the blood-brain barrier. With a total of 15 patents to his name, Furukawa's work is at the forefront of medical innovation.

Latest Patents

Furukawa's latest patents include groundbreaking inventions such as a BBB-crossing lipid ligand of hetero nucleic acid. This invention aims to provide a nucleic acid agent that can be efficiently delivered to the central nervous system, which is typically resistant to drug delivery due to the blood-brain barrier mechanism. The invention includes a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, along with a second nucleic acid strand that is bound to various lipid analogs. Another notable patent involves a nucleic acid complex that efficiently delivers a nucleic acid agent to the central nervous system, providing an antisense effect on a target transcription product at the delivery site.

Career Highlights

Furukawa has worked with notable companies such as NSK Corporation and Takeda Pharmaceutical Company Limited. His experience in these organizations has contributed to his expertise in the field of biotechnology and pharmaceuticals.

Collaborations

Furukawa has collaborated with esteemed colleagues, including Toshiaki Oguchi and Tomoyuki Yanagisawa. Their joint efforts have further advanced the research and development of innovative nucleic acid delivery systems.

Conclusion

Hideki Furukawa's contributions to the field of nucleic acid delivery are invaluable. His innovative patents and collaborations highlight his commitment to advancing medical science and improving therapeutic outcomes.

This text is generated by artificial intelligence and may not be accurate.